| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥136.2B | ¥130.3B | +4.5% |
| Operating Income | ¥10.1B | ¥6.9B | +45.1% |
| Ordinary Income | ¥9.9B | ¥7.5B | +31.7% |
| Net Income | ¥7.1B | ¥8.4B | -15.1% |
| ROE | 4.4% | 5.3% | - |
FY2025 results show revenue of 136.2B yen (YoY +4.5%), operating income of 10.1B yen (YoY +45.1%), ordinary income of 9.9B yen (YoY +31.7%), and net income of 7.1B yen (YoY -15.1%). The company achieved revenue growth for consecutive periods with operating profit margin improving significantly to 7.4%, up 2.1 percentage points from 5.3% in the prior year. While top-line growth and operating profitability showed strong improvement, net income declined due to higher tax burden and extraordinary items. Operating cash flow of 5.3B yen represented a sharp decline of 76.4% YoY, indicating deteriorating cash generation quality.
Revenue increased 5.9B yen to 136.2B yen, driven by growth across most product categories and geographic regions. By product category, Urology products grew 7.9% to 66.1B yen, Digestive products increased 5.9% to 40.7B yen, while Vascular products declined 14.5% to 4.8B yen. By geography, Japan revenue grew 7.1% to 90.2B yen representing 66.2% of total revenue, China declined 7.0% to 31.9B yen, and Europe increased 18.4% to 11.2B yen. The domestic market expansion and European growth offset the China market contraction.
Operating income surged 3.2B yen to 10.1B yen, with operating margin improving to 7.4% from 5.3%. Cost of sales increased 4.3% to 76.2B yen while revenue grew 4.5%, resulting in gross profit margin maintaining at 44.0% versus 43.9% prior year. SG&A expenses increased 6.0B yen to 49.9B yen, representing 36.6% of revenue versus 33.7% prior year, but the absolute operating income improvement demonstrates operating leverage from revenue growth. Depreciation of 5.7B yen resulted in EBITDA of approximately 15.8B yen.
Ordinary income of 9.9B yen declined 0.2B yen from operating income, reflecting net non-operating expenses. Non-operating income totaled 0.6B yen including interest income of 0.2B yen and dividend income of 0.1B yen. Non-operating expenses of 0.7B yen primarily consisted of foreign exchange losses of 0.6B yen, indicating FX headwinds during the period. The net non-operating impact of negative 0.1B yen was relatively minor at 0.1% of revenue.
Net income of 7.1B yen declined 1.3B yen or 15.1% YoY despite the operating profit improvement. Profit before tax reached 10.6B yen after extraordinary items, with extraordinary income of 2.3B yen from asset sales generating gains of 3.0B yen, and extraordinary losses of 1.5B yen including disposal losses of 1.2B yen and securities valuation losses of 0.3B yen. The net extraordinary gain of 0.8B yen represented 11.2% of net income, indicating significant impact from non-recurring factors. Income tax expense of 3.5B yen represented an effective tax rate of 33.0%, higher than typical corporate tax rates. Comprehensive income totaled 10.9B yen including foreign currency translation adjustments of 1.6B yen gain, valuation gains on securities of 0.9B yen, and remeasurement of defined benefit plans of 1.2B yen gain.
This represents a revenue up, operating profit up, but net income down pattern, where operational improvements were offset by higher tax burden and the absence of prior year favorable factors.
The company operates as a single segment focused on disposable catheter and tube manufacturing and sales, therefore segment-level operating income analysis is not applicable. Revenue information by product category shows Urology systems as the core business at 48.6% of total revenue with 66.1B yen, followed by Digestive systems at 29.9% with 40.7B yen. Surgical systems contributed 7.9% at 10.8B yen, Vascular systems 3.5% at 4.8B yen, and Nursing and Testing systems 10.1% at 13.8B yen. The concentration in Urology and Digestive categories represents approximately 78.5% of total revenue, indicating focused product portfolio positioning.
[Profitability] ROE of 4.4% declined from prior year levels, reflecting the net income decrease despite equity base growth. Operating margin improved significantly to 7.4% from 5.3%, up 2.1 percentage points, demonstrating enhanced operational efficiency. Net profit margin of 5.2% compressed from prior year as tax and extraordinary items impacted bottom-line conversion. Gross profit margin held steady at 44.0% versus 43.9% prior year. [Cash Quality] Cash and deposits stood at 58.3B yen, providing 7.29 times coverage of short-term debt of 8.0B yen, indicating strong liquidity buffer. Operating cash flow of 5.3B yen represented 0.74 times net income, below the 0.8 threshold and signaling cash conversion challenges. Cash conversion rate of EBITDA was 0.34, indicating only 34% of EBITDA converted to operating cash flow. [Investment Efficiency] Total asset turnover was 0.68 times, reflecting stable asset utilization. Inventory turnover days extended to 114 days, significantly elevated and indicating inventory management concerns. Days inventory outstanding warning flag was triggered. Cash conversion cycle deteriorated to 245 days, well above typical manufacturing benchmarks of under 90 days. [Financial Health] Equity ratio strengthened to 81.1%, up from 78.6% prior year, reflecting conservative capital structure. Current ratio of 702.7% demonstrates substantial short-term financial strength. Debt-to-equity ratio of 0.05 and net debt-to-equity of negative 0.31 indicate minimal leverage with net cash position. Interest coverage ratio exceeds 100 times given minimal interest expense of 0.1B yen against operating income of 10.1B yen.
Operating cash flow of 5.3B yen declined sharply by 76.4% YoY, representing 0.74 times net income of 7.1B yen and indicating deteriorating earnings quality from a cash perspective. Operating cash flow before working capital changes totaled 8.9B yen, but working capital absorbed 3.6B yen primarily through inventory increase of 5.0B yen, trade receivables increase of 1.7B yen, and trade payables decrease of 0.6B yen. Income taxes paid of 3.9B yen represented 55% of operating cash flow before tax payments, reflecting the elevated tax burden. Interest and dividends received contributed 0.3B yen while interest paid was minimal at 0.1B yen. Investing cash flow of negative 5.7B yen consisted primarily of capital expenditures of 4.1B yen, representing 0.73 times depreciation of 5.7B yen and indicating maintenance-level investment below depreciation run rate. Free cash flow of negative 0.4B yen marks a significant deterioration from profitable operating activities being fully consumed by capex and working capital needs. Financing cash flow of negative 6.0B yen reflected shareholder returns through share repurchases of 2.0B yen and dividend payments. The combination of weak free cash flow and continued shareholder distributions resulted in cash and deposits declining modestly. The cash position of 58.3B yen remains robust at 42.8% of total assets, providing substantial financial flexibility despite the period's cash flow pressures.
Ordinary income of 9.9B yen compared to operating income of 10.1B yen shows net non-operating expenses of approximately 0.2B yen, representing minimal impact at 0.1% of revenue. Non-operating items consisted of financial income including interest income of 0.2B yen and dividend income of 0.1B yen totaling 0.6B yen, offset by foreign exchange losses of 0.6B yen and interest expense of 0.1B yen. The FX losses represent transaction-based volatility rather than structural concerns. Extraordinary items totaled net gain of 0.8B yen, comprising asset sale gains of 3.0B yen offset by disposal losses of 1.2B yen and securities valuation losses of 0.3B yen. These non-recurring factors contributed approximately 11.2% of net income, indicating material impact from one-time events. Operating cash flow of 5.3B yen falling short of net income of 7.1B yen with OCF to net income ratio of 0.74 raises earnings quality concerns. The gap is primarily attributable to working capital deterioration, with inventory increasing 5.0B yen and absorbing cash that would otherwise support earnings quality. The cash conversion rate of 0.34 times EBITDA further confirms that only one-third of EBITDA is converting to cash, suggesting either timing differences in working capital or potential issues with revenue quality recognition. Accruals analysis indicates earnings supported more by accounting accruals than by cash generation, warranting close monitoring of working capital trends in subsequent periods.
Full-year guidance calls for revenue of 139.6B yen (YoY +2.5%), operating income of 10.6B yen (YoY +5.5%), and ordinary income of 10.7B yen (YoY +8.3%). Current period results represent full-year achievement, as fiscal year 2025 data reflects the completed 12-month period ending December 2025. The guidance figures presented appear to represent the next fiscal year forecast. Against this forward guidance, the current period revenue of 136.2B yen suggests the company expects modest 2.5% growth in the coming year, decelerated from the current year's 4.5% growth. Operating income guidance of 10.6B yen represents only 5.5% growth despite the strong 45.1% improvement achieved in the current year, indicating expectation of margin normalization or increased cost pressures. The ordinary income growth forecast of 8.3% exceeds operating income growth, implying anticipated improvement in non-operating items, potentially from reduced FX losses or increased financial income. EPS forecast of 89.44 yen compares to actual EPS of 84.25 yen, implying approximately 6.2% earnings per share growth. Annual dividend forecast of 20.00 yen represents maintenance of the final dividend level, with payout ratio forecast at 40.9%. The conservative revenue growth outlook may reflect management caution regarding market conditions, particularly in China where revenue declined 7.0% in the current period, or inventory normalization initiatives that could constrain near-term shipment growth.
Annual dividend totaled 39.00 yen per share comprising interim dividend of 19.00 yen including a 2.00 yen 50th anniversary commemorative dividend, and year-end dividend of 20.00 yen. This represents an increase from prior year levels, though specific prior year dividend amount is not disclosed. Based on basic EPS of 84.25 yen, the dividend payout ratio calculates to 46.3%, while the reported payout ratio of 40.9% against forecast EPS of 89.44 yen suggests dividend policy targets approximately 40-45% of earnings. Share repurchases totaled 2.0B yen during the period, representing significant capital return alongside dividends. Total shareholder returns combining dividends and buybacks exceeded free cash flow of negative 0.4B yen, indicating returns were funded from existing cash reserves rather than period cash generation. The total return approach demonstrates management commitment to shareholder value despite cash flow pressures, though sustainability depends on operating cash flow recovery. Forecast dividend of 20.00 yen for the next period represents 0.00 yen change from the year-end dividend level, indicating stable dividend policy. Treasury shares outstanding of 1,279K shares against total shares of 9,664K indicates approximately 13.2% of shares held in treasury, providing flexibility for future allocation decisions.
Working capital deterioration presents the most quantifiable risk, with inventory days of 114 days exceeding healthy levels and cash conversion cycle of 245 days consuming significant cash resources. The inventory increase of 5.0B yen absorbed 94% of operating cash flow, and if demand patterns do not materialize to consume this inventory, writedown risks or price pressure to clear stock could impact future profitability. Current finished goods inventory of 23.8B yen represents approximately 17.5% of revenue, elevated for a disposable medical device manufacturer.
Geographic concentration risk is evident with Japan representing 66.2% of revenue and China market declining 7.0% in the current period. The China revenue deterioration of 2.4B yen offset domestic growth, and further weakness in this second-largest market could constrain overall growth prospects. Political tensions, regulatory changes, or competitive dynamics in China pose material revenue headwinds given the 23.4% revenue exposure.
Short-term debt refinancing risk emerges from the 100% short-term liability composition, with all 8.0B yen of interest-bearing debt classified as short-term borrowing. While current cash coverage of 7.29 times provides substantial cushion, dependency on annual refinancing exposes the company to potential interest rate increases or credit market disruptions. The company's strong equity base of 81.1% and minimal leverage mitigates this risk, but warrants monitoring if debt levels increase.
[Industry Position] (Reference - Proprietary Analysis)
The company operates in the medical device manufacturing sector specializing in disposable catheters and tubes. Operating margin of 7.4% positions in the mid-range for medical device manufacturers, which typically exhibit margins between 5-15% depending on product mix and scale. The gross margin of 44.0% aligns with disposable medical device industry standards where material costs and manufacturing complexity drive cost structures. ROE of 4.4% falls below medical device industry medians of approximately 8-12%, reflecting the company's conservative capital structure with 81.1% equity ratio compared to industry median leverage that typically employs more debt. The equity ratio of 81.1% significantly exceeds industry median of approximately 50-60%, indicating underleveraged capital structure that could support higher returns with modest debt utilization. Revenue growth of 4.5% tracks with medical device industry growth rates in mature markets, though specialty device manufacturers often achieve higher growth through innovation and market expansion. Operating cash flow to net income ratio of 0.74 falls short of industry best practices of exceeding 0.8, with inventory management being the primary differentiator as industry leaders typically maintain inventory days below 60 compared to the company's 114 days. The medical device sector benchmark for cash conversion cycles averages 90-120 days, meaning the company's 245-day cycle represents significant underperformance and opportunity for operational improvement. Dividend payout ratio of 40-45% aligns with mature medical device company practices of returning 30-50% of earnings while retaining capital for R&D and growth investments.
[Key Takeaways from Earnings]
Strong operational leverage demonstrated through 45.1% operating income growth on 4.5% revenue growth indicates the company successfully absorbed fixed costs and improved manufacturing efficiency. Operating margin expansion of 2.1 percentage points to 7.4% while maintaining gross margin at 44.0% suggests effective SG&A cost management despite absolute expense increases. This operational improvement trajectory, if sustained, could drive meaningful profit expansion as revenue growth continues.
Working capital management deterioration represents the most significant structural concern, with inventory days reaching 114 days and cash conversion cycle extending to 245 days. The 5.0B yen inventory build consumed 94% of operating cash flow, transforming what would have been robust 10.5B yen cash generation into constrained 5.3B yen actual cash flow. Operating cash flow to net income ratio of 0.74 and EBITDA cash conversion of 0.34 indicate only one-third of economic profits convert to cash. This working capital intensity creates vulnerability to demand shocks and limits financial flexibility despite strong balance sheet. Management's ability to reduce inventory levels and accelerate cash conversion will determine whether the operational profit improvements translate to sustainable value creation.
Capital allocation demonstrates shareholder-friendly orientation through 2.0B yen share repurchases and increased dividends totaling 3.3B yen, exceeding free cash flow generation and drawing on cash reserves. Combined with the conservative 81.1% equity ratio and net cash position, the financial policy prioritizes stability and shareholder returns over growth investment, as evidenced by capex of 4.1B yen running below depreciation of 5.7B yen. This capital-light approach with 0.73 times capex-to-depreciation ratio suggests mature business positioning with limited expansion investment, though adequate for maintaining current operations. The sustainability of enhanced shareholder returns depends on working capital efficiency improvements to restore positive free cash flow generation.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.